IL6 and ovarian carcinoma: All the isolates were evaluated for their ability to inhibit IL-6 activity in the human embryonic kidney-BlueTM IL-6 cell line and their cytotoxic activity against ovarian cancer cell lines (SKOV3/SKOV3-TR) and chemotherapy-resistant variants (cisplatin-resistant A2780/paclitaxel-resistant SKOV3).